Back
ESC Premium Access

SGLT2 inhibitors: uncovering the mechanisms of cardiovascular risk reduction

Session: Spotlight on the effects of SGLT2 inhibition in heart failure (EBAC accredited)
Topic: Pathophysiology and Mechanisms
Speaker: Professor S. Verma (Toronto, CA)
Supported by an unrestricted educational grant from AstraZeneca
Event: ESC Congress 2019

Congress Presentation

About the speaker

Professor Subodh Verma

St. Michael's Hospital, Toronto (Canada)
27 presentations
0 follower

4 more presentations in this session

The hidden burden of heart failure

Speaker: Professor F. Ruschitzka (Zurich, CH)

Access
Slides
Video
Thumbnail

The clinical impact of SGLT2 inhibitor cardiovascular outcomes trials

Speaker: Doctor M. Bonaca (Aurora, US)

Access
Slides
Video
Thumbnail

Lighting the way to the future of heart failure management

Speaker: Doctor M. Kosiborod (Kansas City, US)

Access
Slides
Video
Thumbnail

Questions and answers

Speaker: Professor F. Ruschitzka (Zurich, CH) Doctor M. Bonaca (Aurora, US) Professor S. Verma (Toronto, CA) Doctor M. Kosiborod (Kansas City, US)

Access
Slides
Video
Thumbnail

Access the full session

Spotlight on the effects of SGLT2 inhibition in heart failure (EBAC accredited)

Speakers: Professor S. Verma, Professor F. Ruschitzka, Doctor M. Bonaca, Doctor M. Kosiborod, Professor F. Ruschitzka...
Access
Thumbnail

About the event

Image

ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb